in vitro News and Research

RSS

Transthyretin discovery may halt progression of Alzheimer's

In a finding that may cause a dramatic shift in the way scientists and researchers search for a therapy for Alzheimer's disease, a team of researchers led by Jeff Johnson, an associate professor at the School of Pharmacy, has discovered that increased expression of a protein called transthyretin in the brain appears to halt the progression of the disease.

10 Sep 2004

Sinovac completes dosing in phase 1 human clinical testing of SARS vaccine

Sinovac Biotech Ltd. has announced that all 36 subjects of the Phase I human clinical trial for its inactivated SARS vaccine have now been vaccinated with two doses of either SARS vaccine or placebo.

7 Sep 2004

Chemotherapy experts refute ASCO recommendations on use of drug sensitivity and resistance assays

A group of leading chemotherapy experts assembled as the Clinical Oncologists for Individualized Therapy (COFIT) refute the findings of the American Society of Clinical Oncology (ASCO) technology assessment panel regarding the use of chemotherapy sensitivity and resistance assays (CSRAs).

1 Sep 2004

Solid evidence that best treatment for multiple sclerosis is pregnancy

For years, doctors have suggested the best treatment for multiple sclerosis is pregnancy. Now, an Oregon study is delivering solid evidence to support the theory.

27 Aug 2004

Nobox gene key to proper egg development

While humorists ponder the old saw about the chicken and the egg, researchers at Baylor College of Medicine focus on the egg, which would not exist without the master geneNobox, which they describe in this week’s issue of the journal Science.

27 Aug 2004

Phase 1 clinical trial of new anticancer drug from Human Genome Sciences

Human Genome Sciences has begun dosing patients in a Phase 1 clinical trial of HGS-TR2J, a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.

25 Aug 2004

Regular exercise boosts immune system in older men

As it turns out, judging by the reaction strength of their immune system to an unknown, but harmless, protein antigen, it’s possible for men over 70 to mount an immune response similar to that produced by much younger men -- if they get regular moderate physical activity of about six hours a week.

25 Aug 2004

No adverse side-effects have been observed in clinical trial of SARS vaccine

Sinovac Biotech has announced that all 36 subjects of the Phase I human clinical trial for its inactivated SARS vaccine have now been vaccinated with either SARS vaccine or placebo.

11 Aug 2004

What is Telomere crisis?

Telomere crisis is an important early event in the development of breast cancer, and its occurrence can be identified with precision, according to recent findings by a team of scientists at the Department of Energy's Lawrence Berkeley National Laboratory and the University of California at San Francisco.

11 Aug 2004

Research unlocks the mystery of the miraculous healing powers of honey

A Sydney researcher has unlocked the mystery of the miraculous healing powers of honey, adding to the calls for its use as a first line defence against serious infection.

11 Aug 2004

New treatment strategy for brain cancer

Virginia Commonwealth University Massey Cancer Center researchers have found that combining ionizing radiation with a secreted protein that selectively inhibits tumor cell growth and survival can target cancer cells and leave healthy cells alone, perhaps presenting a new approach for treating the deadliest type of brain tumor.

9 Aug 2004

Recommendation against the use of chemotherapy sensitivity and resistance assays

A new technology assessment from the American Society of Clinical Oncology states that the use of chemotherapy sensitivity and resistance assays (CSRAs) to select chemotherapeutic agents for cancer patients should not be undertaken outside of the clinical trial setting.

3 Aug 2004

IVF pioneer wins international recognition

Monash in vitro fertilisation pioneer Professor Alan Trounson has been awarded the 2004 Bertarelli Foundation Award in Reproductive Health for his outstanding contribution to the field of assisted reproductive technologies.

29 Jul 2004

Patent pending botanical extract, V38-AMF-1, completely inhibits bird flu (H5N1) and Fujian Flu

PRB Pharmaceuticals and Lee's Pharmaceuticals have announced the discovery that PRB'S patent pending botanical extract, V38-AMF-1, completely inhibits bird flu (H5N1) and Fujian Flu (H3N2) infections in vitro.

29 Jul 2004

New Caledonian sponges produce antimalarial substances

Marine organisms synthesize many different substances, some of which possess anticarcinogenic, antiviral or antiparasitic properties.

22 Jul 2004

Australian collaboration to produce cancer immunotherapy vaccines

A Brisbane based biomedical company, Tissue Therapies Limited (TIS) and the Queensland Institute of Medical Research (QIMR) have agreed on the terms of a new collaboration aimed at developing Tissue Therapies' VitroGro® cell growth technology as a platform to produce cancer immunotherapy vaccines.

21 Jul 2004

New compound that is designed to overcome Gleevec resistance

One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.

17 Jul 2004

Animal bone implants that resemble natural bone

A team of researchers at the Institute of Bioengineering and Nanotechnology (IBN) has moved one step closer to developing an ideal bone scaffold for reconstructive surgery.

15 Jul 2004

Latest findings on HIV pathogenesis at AIDS Conference in Bangkok

At the XVth International AIDS Conference in Bangkok, Thailand, Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases and chief of the NIAID Laboratory of Immunoregulation (LIR), will present his laboratory’s latest findings on how aberrant immune activation underlies HIV pathogenesis.

15 Jul 2004

Natural products to be developed as anti-cancer therapeutics

The licence grants Zentaris exclusive worldwide rights for the development, manufacture and marketing of disorazoles, a novel class of natural products with strong anti-cancer potential discovered by GBF researchers.

8 Jul 2004